ClinicalTrials.gg

Biliary Tract Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 521 studies for Biliary Tract Neoplasms across more than 10 countries. 201 are recruiting or about to start. 315 of them are mainly about Biliary Tract Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Gallbladder Neoplasms: 892 studies, 278 open.

ClinicalTrials.gov finds 1,109 studies for Biliary Tract Neoplasms. How that becomes 519 here

This page counts the studies the registry files under Biliary Tract Neoplasms, and those it files under no condition that list Biliary Tract Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,109Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −364Filed under a narrower condition, counted on its own pageGallbladder Neoplasms 233 · Bile Duct Neoplasms 131
  3. −3List Biliary Tract Neoplasms as a condition, but the registry did not file them under itMost often written as “Advanced Biliary Tract Cancer” (1), “Advanced Biliary Tract Cancer(BTC)” (1), and “Liver and Intrahepatic Biliary Tract Cancer” (1). The registry filed them under other conditions only, most often Neuroendocrine Tumors (1) and Genital Neoplasms, Female (1).
  4. −223Match it another way35 name it in the title, 4 in a keyword, and 184 by a synonym or other text the search reads.
  5. 519The count on this page35 of them list Biliary Tract Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
161
Recruiting
141
Not yet recruiting
58
Status unknown
53
Active, not recruiting
44
Terminated
40

Phase

Phase 2
303
Phase 1
115
Phase 3
40
Phase 4
7
Early Phase 1
1

Where

China
176
United States
155
Korea, Republic of
96
Japan
50
Spain
46
France
45

Who develops what

Add Biliary Tract Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 34 programs from 26 companies, 14 with this as their studies’ main aim; 9 with a live phase 3 study; 9 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Sichuan Biokin Pharmaceutical and AstraZeneca here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GemcitabineRecent, repeated
Evidence
  • NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · background · “Gemcitabine” · registered Jul 2026
  • NCT07398339 · Shanghai Guangsheng Biopharmaceutical Co., Ltd · Phase 2 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Jan 2026
  • NCT07229625 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Nov 2025
  • NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Aug 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed912 studies
CisplatinRecent, repeated
Evidence
  • NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · background · “Cisplatin” · registered Jul 2026
  • NCT07398339 · Shanghai Guangsheng Biopharmaceutical Co., Ltd · Phase 2 · live · background · “Cisplatin for injection” · registered Jan 2026
  • NCT07229625 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Cisplatin Injection” · registered Nov 2025
  • NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Cisplatin for Injection” · registered Aug 2025
  • NCT06591520 · Akeso · Phase 3 · live · comparator · “Durvalumab, Gemcitabine, Cisplatin” · registered Sep 2024
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed912 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · comparator · “Pembrolizumab” · registered Jul 2026
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT06978114 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered May 2025
  • NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Pembrolizumab” · registered Feb 2024
  • NCT05429697 · SMT bio Co., Ltd. · Phase 3 · live · background · “Pembrolizumab” · registered Jun 2022
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)55 studies
durvalumabRecent, repeated
Evidence
  • NCT07710885 · Otsuka Holdings Co., Ltd. · Phase 3 · live · comparator · “Durvalumab” · registered Jul 2026
  • NCT07229625 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Durvalumab Injection” · registered Nov 2025
  • NCT06591520 · Akeso · Phase 3 · live · comparator · “Durvalumab, Gemcitabine, Cisplatin” · registered Sep 2024
  • NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Durvalumab” · registered Feb 2024
  • NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Durvalumab” · registered Feb 2023
AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018)55 studies
CapecitabineRecent, repeated
Evidence
  • NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Capecitabine Tablets” · registered May 2026
  • NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Capecitabine” · registered May 2026
  • NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Capecitabine Tablets” · registered Aug 2025
  • NCT06622057 · InnoPharmax Inc. · Phase 3 · live · background · “Capecitabine” · registered Sep 2024
  • NCT06109779 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Oct 2023
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized46 studies
BevacizumabRecent, repeated
Evidence
  • NCT06465563 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab Injection” · registered Jun 2024
  • NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Feb 2023
  • NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
  • NCT03929666 · Jazz Pharmaceuticals · Phase 2 · background · “Bevacizumab” · registered Feb 2019
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others44 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT05771480 · AstraZeneca · Phase 3 · live · background · “Gemcitabine + cisplatin + albumin-bound paclitaxel” · registered Mar 2023
  • NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Abraxane” · registered Jul 2022
  • NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Nab-Paclitaxel” · registered Jan 2022
  • NCT04683939 · BioNTech SE · Phase 2 · background · “Nab-paclitaxel” · registered Dec 2020
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)44 studies
FluorouracilRecent, repeated
Evidence
  • NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Fluorouracil” · registered May 2026
  • NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Fluorouracil” · registered May 2026
  • NCT06428409 · Merck & Co., Inc · Phase 2 · live · background · “Fluorouracil (5-FU)” · registered May 2024
  • NCT06219941 · AstraZeneca · Phase 2 · live · background · “5-Fluorouracil” · registered Nov 2023
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “5-Fluorouracil” · registered Jul 2022
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed35 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Oxaliplatin” · registered May 2026
  • NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Oxaliplatin” · registered May 2026
  • NCT07151872 · Qilu Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Oxaliplatin Injection” · registered Aug 2025
  • NCT05771480 · AstraZeneca · Phase 3 · live · background · “Gemcitabine + oxaliplatin” · registered Mar 2023
  • NCT03929666 · Jazz Pharmaceuticals · Phase 2 · background · “Oxaliplatin” · registered Feb 2019
Sanofi35% of its industry studies34 studies
IrinotecanRecent, repeated
Evidence
  • NCT07606599 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan Hydrochloride” · registered May 2026
  • NCT07582315 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan Hydrochloride” · registered May 2026
  • NCT06219941 · AstraZeneca · Phase 2 · live · background · “Irinotecan” · registered Nov 2023
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)34 studies
PaclitaxelRecent, repeated
Evidence
  • NCT05506943 · Compass Therapeutics · Phase 3 · live · background · “Paclitaxel” · registered Aug 2022
  • NCT05482893 · Phanes Therapeutics · Phase 2 · live · background · “Paclitaxel” · registered Jul 2022
  • NCT04644068 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Oct 2020
  • NCT03314935 · Incyte Corporation · Phase 2 · background · “Paclitaxel” · registered Oct 2017
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed22 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
  • NCT05771480 · AstraZeneca · Phase 3 · live · background · “Gemcitabine + carboplatin” · registered Mar 2023
  • NCT05489211 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2022
  • NCT04956640 · Eli Lilly and Company · Phase 2 · live · background · “Carboplatin” · registered Jul 2021
  • NCT04644068 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Oct 2020
Eli Lilly and Company16% of its industry studies23 studies
CetuximabRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
  • NCT06024174 · Bristol-Myers Squibb · Phase 2 · background · “Cetuximab” · registered Aug 2023
Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004)22 studies
atezolizumabRecent, repeated
Evidence
  • NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Feb 2023
  • NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Atezolizumab” · registered Jan 2022
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)22 studies

22 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
nanvuranlat☆ Track1 live phase-3 study: NCT07265674J-Pharma Co., Ltd.
rilvegostomig☆ Track3 live phase-3 studies: NCT06109779, NCT06467357, NCT07221253AstraZeneca
trastuzumab brengitecan☆ Track1 live phase-3 study: NCT07606599Sichuan Biokin Pharmaceutical Co., Ltd.
izalontamab brengitecan☆ Track1 live phase-3 study: NCT07582315Sichuan Biokin Pharmaceutical Co., Ltd.
adebrelimab☆ Track1 live phase-3 study: NCT07229625Jiangsu HengRui Medicine Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 34 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (9)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Dec 2026 est.adebrelimab · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimstudied with Gemcitabinestudied with Cisplatinstudied with BevacizumabNCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer — primary endpoint: Objective Response Rate (ORR) · 93 enrolled
  • 30 Dec 2026 est.Anti-Claudin 18.2 Antibody-drug Conjugate ASP546C · Astellas Pharma Inc · Phase 2 named, not the main aimNCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. — primary endpoint: Phase I (Dose Escalation):To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of XNW27011 · 240 enrolled
  • 14 Mar 2027 est.EB-HC01 dual-target CARNK cells · Beijing Biotech · Phase 2 named, not the main aimstudied with fludarabinestudied with CyclophosphamideNCT07641036 Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer — primary endpoint: Dose-Limiting Toxicities · 30 enrolled

6 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Biliary Tract Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 40 open · Tyrosine kinase inhibitors (TKIs) 19 open · Antimetabolites 16 open · Antibody-drug conjugates (ADCs) 10 open · Antimitotic agents 2 open

Coming up

75studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 141 Biliary Tract Neoplasms studies recruiting now, 81 (57%) set no upper age limit and 37 (26%) stop at 75 or younger. 6 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (3%) take healthy volunteers.

Recruiting studies that take each age, of 141
AgeWomenMen
104 (3%)4 (3%)
18131 (93%)131 (93%)
30140 (99%)140 (99%)
40141 (100%)141 (100%)
50141 (100%)141 (100%)
65141 (100%)141 (100%)
75136 (96%)136 (96%)
8592 (65%)92 (65%)

Across all 521 studies, recruiting or not: 18% stop at 75 or younger and <1% at 65; 3% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Biliary Tract Neoplasms studies take

Of 130 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 137 mo30–… · 34 studies——
Phase 1/260 mo33–68 · 48 studies——
Phase 239 mo29–68 · 130 studies—39 mo29–60 · 100 studies
Interventional, no phase35 mo26–63 · 25 studies——
Observational58 mo37–132 · 44 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 521. Browse all 521 → or search them.